VEGFA and neoplasm: It is worth mentioning the study carried out by D’Alessandris et al. in which, despite not giving positive results, the administration of BEV and erlotinib was tailored to the molecular profile of the patient’s tumor (VEGF overexpressing tumors or EGFRvIII tumors, respectively) [436].